In 2026, China’s patent system continues to provide a robust framework for protecting
high-tech innovations in medical devices, supporting both domestic and international
companies. Governed by the Patent Law of the People’s Republic of China (latest
amendment 2021) and administered by the China National Intellectual Property
Administration (CNIPA), the system enables rapid protection, enforceability, and
commercialization opportunities for strategic technologies. The following case demonstrates
how proactive patent management and enforcement can safeguard cutting-edge medical
device innovations while creating commercial value.
Case Overview: Mindray’s Intelligent Patient Monitor Patents
Mindray, a leading Chinese medical device manufacturer, developed an advanced intelligent
patient monitoring system capable of real-time multi-parameter analysis and predictive
alerts for critical care units. The system incorporated several proprietary technologies,
including algorithms for signal processing and sensor integration. Mindray had registered
both invention patents covering the core algorithms and utility model patents for sensor
configurations with CNIPA.
In 2024, several smaller competitors began producing similar monitoring devices that
replicated the sensor layout and predictive algorithms without authorization. Mindray immediately
initiated a dual enforcement approach. First, administrative complaints were filed with CNIPA and
local IP offices, leveraging registered patents to obtain rapid takedown orders against infringing
products distributed online and through regional hospitals. Concurrently, Mindray pursued
civil litigation in the Shanghai Intellectual Property Court, requesting injunctions and damages.
Within six months, the court ruled in favor of Mindray, granting both injunctive relief and
substantial financial compensation. The enforcement action not only protected Mindray’s
market share but also reinforced the commercial value of strategic patent registration.
Strategic Insights from the Case
This case illustrates several practical lessons for medical technology innovators in China. Filing
invention patents for core technological components ensures long-term protection, while utility
model patents provide rapid leverage in administrative actions. Detailed technical
documentation, precise claims, and continuous portfolio monitoring enabled Mindray to respond
swiftly to infringement, minimizing business disruption. Furthermore, combining administrative
enforcement with civil litigation proved effective in securing both immediate and durable protection.
Practical Guidance for Global Innovators
For international medical device companies entering China, several strategies are critical: filing
patents before public disclosure to avoid invalidation risks, leveraging both invention and utility
model patents for layered protection, and monitoring CNIPA databases to detect competitor filings.
Engaging local IP counsel is essential for administrative procedures, civil litigation, and cross-border
enforcement. Additionally, companies should explore licensing opportunities to generate revenue
from high-value technologies, taking advantage of China’s evolving patent commercialization
ecosystem.
Conclusion
China’s patent environment in 2026 provides an increasingly effective platform for high-tech
medical device protection. Mindray’s case underscores the importance of a strategic, well-managed
patent portfolio, combining careful claim drafting, proactive enforcement, and commercialization
strategies. By implementing these measures, innovators can safeguard critical technologies, maintain
competitive advantage, and leverage intellectual property as a tangible business asset.
Hyperlink List：
●IPcrossark:
https://www.ipcrossark.com/en/patent_detail/1.html
● China National Intellectual Property Administration (CNIPA) – Patent Services:
● Mindray：
